These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26379170)

  • 21. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Efficacy of Cognitive Intervention in Mild Cognitive Impairment (MCI): a Meta-Analysis of Outcomes on Neuropsychological Measures.
    Sherman DS; Mauser J; Nuno M; Sherzai D
    Neuropsychol Rev; 2017 Dec; 27(4):440-484. PubMed ID: 29282641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
    Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
    Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-home walking speeds and variability trajectories associated with mild cognitive impairment.
    Dodge HH; Mattek NC; Austin D; Hayes TL; Kaye JA
    Neurology; 2012 Jun; 78(24):1946-52. PubMed ID: 22689734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unobtrusive measurement of daily computer use to detect mild cognitive impairment.
    Kaye J; Mattek N; Dodge HH; Campbell I; Hayes T; Austin D; Hatt W; Wild K; Jimison H; Pavel M
    Alzheimers Dement; 2014 Jan; 10(1):10-7. PubMed ID: 23688576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
    Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
    J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials.
    Verma N; Beretvas SN; Pascual B; Masdeu JC; Markey MK;
    Curr Alzheimer Res; 2018 Mar; 15(5):429-442. PubMed ID: 29110613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease.
    Siafarikas N; Selbaek G; Fladby T; Šaltytė Benth J; Auning E; Aarsland D
    Int Psychogeriatr; 2018 Jan; 30(1):103-113. PubMed ID: 28927477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease.
    Xiong C; Weng H; Bennett DA; Boyle PA; Shah RC; Fague S; Hall CB; Lipton RB; Morris JC
    Neuroepidemiology; 2014; 43(2):131-9. PubMed ID: 25376544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using Neuropsychological Process Scores to Identify Subtle Cognitive Decline and Predict Progression to Mild Cognitive Impairment.
    Thomas KR; Edmonds EC; Eppig J; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2018; 64(1):195-204. PubMed ID: 29865077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument.
    Amariglio RE; Donohue MC; Marshall GA; Rentz DM; Salmon DP; Ferris SH; Karantzoulis S; Aisen PS; Sperling RA;
    JAMA Neurol; 2015 Apr; 72(4):446-54. PubMed ID: 25706191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current State of Digital Biomarker Technologies for Real-Life, Home-Based Monitoring of Cognitive Function for Mild Cognitive Impairment to Mild Alzheimer Disease and Implications for Clinical Care: Systematic Review.
    Piau A; Wild K; Mattek N; Kaye J
    J Med Internet Res; 2019 Aug; 21(8):e12785. PubMed ID: 31471958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic differentiation of mild cognitive impairment due to Alzheimer's disease using a hippocampus-dependent test of spatial memory.
    Moodley K; Minati L; Contarino V; Prioni S; Wood R; Cooper R; D'Incerti L; Tagliavini F; Chan D
    Hippocampus; 2015 Aug; 25(8):939-51. PubMed ID: 25605659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
    Marizzoni M; Ferrari C; Macis A; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Pizzini F; Rossini PM; Salvatore M; Schönknecht P; Soricelli A; Del Percio C; Hensch T; Hegerl U; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
    J Alzheimers Dis; 2019; 69(1):49-58. PubMed ID: 30958351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study.
    Harrison JE; Rentz DM; Brashear HR; Arrighi HM; Ropacki MT; Liu E
    J Prev Alzheimers Dis; 2018; 5(4):236-244. PubMed ID: 30298182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting progression from mild cognitive impairment to Alzheimer's disease on an individual subject basis by applying the CARE index across different independent cohorts.
    Chen J; Chen G; Shu H; Chen G; Ward BD; Wang Z; Liu D; Antuono PG; Li SJ; Zhang Z;
    Aging (Albany NY); 2019 Apr; 11(8):2185-2201. PubMed ID: 31078129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease.
    Darby D; Brodtmann A; Woodward M; Budge M; Maruff P
    Int Psychogeriatr; 2011 Nov; 23(9):1376-85. PubMed ID: 21477408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.